CATT CONCLUSION -- SOURCE stephan ryan 5th ed 1) In contrast to the first-year results, longer-term follow-up suggests that as-needed therapy is somewhat less effective than monthly therapy overall in terms of visual gain. 2) Visual acuity and visual gain are associated with, but do not closely mirror retinal thickness or the presence of fluid. 3) One year of monthly therapy does not appear to confer lesion stability when subsequently changing to as-needed therapy. 4) When given as needed, bevacizumab is required more frequently, on average 1.5 more injections over the two-year period. 5) Geographic atrophy occurs with greater frequency in patients receiving monthly therapy. max with lucentis monthly 6) Spectral domain OCT does not appear to increase the accuracy of identifying retinal fluid by the treating physician. 7) Endophthalmitis occurs at similar rates in ranibizumab- and bevacizumab-treated patients, although (as one may expect) it is appears to be associated with an increased rate of injections, occurring most often in patients treated monthly. The increased rate of systemic serious adverse events in bevacizumab persisted in the second year. The authors remained unsure of the reason for the increased risk ratio of systemic adverse events. As in the first year, the rate of vascular events previously associated with anti-VEGF therapy was similar in both groups.
Posted on: Mon, 17 Jun 2013 18:34:22 +0000
Trending Topics
Recently Viewed Topics
© 2015